InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

- Current share price for RCE : $0.375

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$115 Placement & SPP to raise $10 million - Funded to FY26 2 Jul 2024 10:23AM $0.600 $0.375 fallen by 37.50%
$115 Trading Halt 1 Jul 2024 9:33AM $0.600 $0.375 fallen by 37.50%
$115 Clarification - Phase I/II UTI/Urosepsis Fast Infusion Trial 1 Jul 2024 9:07AM $0.600 $0.375 fallen by 37.50%
$115 Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete 28 Jun 2024 9:21AM $0.570 $0.375 fallen by 34.21%
$115 Ethics Approval Broadens to All Topical Infections 24 Jun 2024 9:55AM $0.575 $0.375 fallen by 34.78%
$115 Further R&D Rebate Approved 18 Jun 2024 2:40PM $0.583 $0.375 fallen by 35.62%
$115 R327 added to WHO List of Antibacterial Products 18 Jun 2024 10:04AM $0.550 $0.375 fallen by 31.82%
$115 Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial 11 Jun 2024 8:39AM $0.565 $0.375 fallen by 33.63%
$115 Military Health Research Symposium Abstract & Presentation 3 Jun 2024 9:57AM $0.585 $0.375 fallen by 35.90%
$115 Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort 15 May 2024 11:46AM $0.615 $0.375 fallen by 39.02%
$115 Cleansing Statement 10 May 2024 6:14PM $0.640 $0.375 fallen by 41.41%
$115 Application for quotation of securities - RCE 10 May 2024 6:06PM $0.640 $0.375 fallen by 41.41%
$115 MCRI Pilot Study- Positive Efficacy Data for Lung Infections 9 May 2024 12:31PM $0.645 $0.375 fallen by 41.86%
$115 China Patent Granted for RECCE Anti-Infectives 7 May 2024 8:38AM $0.660 $0.375 fallen by 43.18%
$115 Safety Committee Approves High Dose of 4,000mg 26 Apr 2024 9:42AM $0.685 $0.375 fallen by 45.26%
$115 Quarterly Activities/Appendix 4C Cash Flow Report 22 Apr 2024 9:15AM $0.530 $0.375 fallen by 29.25%
$115 Cleansing Statement 16 Apr 2024 7:03PM $0.550 $0.375 fallen by 31.82%
$115 Application for quotation of securities - RCE 16 Apr 2024 7:00PM $0.550 $0.375 fallen by 31.82%
$115 Recce Completes 5,000 R327 Doses Per Week under GMP 16 Apr 2024 9:45AM $0.495 $0.375 fallen by 24.24%
$115 Recce Pharmaceuticals - Business Update 8 Apr 2024 8:41AM $0.450 $0.375 fallen by 16.67%
$115 Patent Granted in Israel for RECCE Anti-Infectives 3 Apr 2024 9:52AM $0.440 $0.375 fallen by 14.77%
$115 RECCE Trademark Registered - Canada 21 Mar 2024 10:47AM $0.440 $0.375 fallen by 14.77%
$115 Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial 15 Mar 2024 10:17AM $0.420 $0.375 fallen by 10.71%
$115 Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial 12 Mar 2024 12:08PM $0.440 $0.375 fallen by 14.77%
$115 Recce Receives AUD $11.17m R&D Advance 8 Mar 2024 10:18AM $0.440 $0.375 fallen by 14.77%

151 - 175 of 725 results

Page 7 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.